Temat: "Angiotensin II Type 1 Receptor Blockers" - OpacWWW

Skocz do pozycji: 1 1.

Tytuł :: A pressor dose of angiotensin II has no influence on the angiotensin-converting enzyme 2 and other molecules associated with SARS-CoV-2 infection in mice.
Autorzy :: Wang Y; Department of Geriatric and General Medicine, Osaka University Graduate School of Medicine, Suita, Japan.
Takeshita H; Department of Geriatric and General Medicine, Osaka University Graduate School of Medicine, Suita, Japan.
Yamamoto K; Department of Geriatric and General Medicine, Osaka University Graduate School of Medicine, Suita, Japan.
Huang Y; Department of Geriatric and General Medicine, Osaka University Graduate School of Medicine, Suita, Japan.
Wang C; Department of Geriatric and General Medicine, Osaka University Graduate School of Medicine, Suita, Japan.
Nakajima T; Department of Geriatric and General Medicine, Osaka University Graduate School of Medicine, Suita, Japan.
Nozato Y; Department of Geriatric and General Medicine, Osaka University Graduate School of Medicine, Suita, Japan.
Fujimoto T; Department of Geriatric and General Medicine, Osaka University Graduate School of Medicine, Suita, Japan.
Yokoyama S; Department of Geriatric and General Medicine, Osaka University Graduate School of Medicine, Suita, Japan.
Hongyo K; Department of Geriatric and General Medicine, Osaka University Graduate School of Medicine, Suita, Japan.
Nakagami F; Department of Geriatric and General Medicine, Osaka University Graduate School of Medicine, Suita, Japan.
Akasaka H; Department of Geriatric and General Medicine, Osaka University Graduate School of Medicine, Suita, Japan.
Takami Y; Department of Geriatric and General Medicine, Osaka University Graduate School of Medicine, Suita, Japan.
Takeya Y; Department of Geriatric and General Medicine, Osaka University Graduate School of Medicine, Suita, Japan.
Sugimoto K; Department of Geriatric and General Medicine, Osaka University Graduate School of Medicine, Suita, Japan.
Rakugi H; Department of Geriatric and General Medicine, Osaka University Graduate School of Medicine, Suita, Japan.; Pokaż więcej
Źródło :: FASEB journal : official publication of the Federation of American Societies for Experimental Biology [FASEB J] 2021 Mar; Vol. 35 (3), pp. e21419.
Typ publikacji :: Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :: SARS-CoV-2*
Angiotensin II/*pharmacology
Angiotensin II Type 1 Receptor Blockers/*pharmacology
Angiotensin-Converting Enzyme 2/*metabolism
COVID-19/*metabolism
Losartan/*pharmacology
ADAM17 Protein/genetics ; ADAM17 Protein/metabolism ; Angiotensin II/administration & dosage ; Angiotensin II Type 1 Receptor Blockers/administration & dosage ; Angiotensin-Converting Enzyme 2/genetics ; Animals ; Furin/genetics ; Furin/metabolism ; Gene Expression Regulation, Enzymologic/drug effects ; Losartan/administration & dosage ; Male ; Mice ; Mice, Inbred C57BL ; Mice, Knockout ; Serine Endopeptidases/genetics ; Serine Endopeptidases/metabolism ; Vasoconstrictor Agents/pharmacology
: Czasopismo naukowe

Szczegóły

Skocz do pozycji: 2 2.

Tytuł :: Design and optimization of candesartan loaded self-nanoemulsifying drug delivery system for improving its dissolution rate and pharmacodynamic potential.
Autorzy :: Verma R; Department of Pharmaceutical Sciences, Maharshi Dayanand University, Rohtak, Haryana, India.
Kaushik D; Department of Pharmaceutical Sciences, Maharshi Dayanand University, Rohtak, Haryana, India.; Pokaż więcej
Źródło :: Drug delivery [Drug Deliv] 2020 Dec; Vol. 27 (1), pp. 756-771.
Typ publikacji :: Journal Article
MeSH Terms :: Drug Design*
Angiotensin II Type 1 Receptor Blockers/*administration & dosage
Benzimidazoles/*administration & dosage
Blood Pressure/*drug effects
Drug Delivery Systems/*methods
Tetrazoles/*administration & dosage
Angiotensin II Type 1 Receptor Blockers/chemistry ; Angiotensin II Type 1 Receptor Blockers/pharmacology ; Animals ; Benzimidazoles/chemistry ; Benzimidazoles/pharmacology ; Biological Availability ; Dose-Response Relationship, Drug ; Drug Carriers/chemistry ; Drug Liberation ; Drug Stability ; Emulsions ; Excipients/chemistry ; Food-Drug Interactions ; Male ; Rats, Wistar ; Solubility ; Tetrazoles/chemistry ; Tetrazoles/pharmacology
: Czasopismo naukowe

Szczegóły Pełny tekst Pełny tekst

Skocz do pozycji: 3 3.

Tytuł :: Angiotensin Receptor Neprilysin Inhibitors-2019 Update.
Autorzy :: Chalikias G; Cardiology Department, Medical School, Democritus University of Thrace, Dragana, 68100, Alexandroupolis, Greece.
Tziakas D; Cardiology Department, Medical School, Democritus University of Thrace, Dragana, 68100, Alexandroupolis, Greece. .; Pokaż więcej
Źródło :: Cardiovascular drugs and therapy [Cardiovasc Drugs Ther] 2020 Oct; Vol. 34 (5), pp. 707-722.
Typ publikacji :: Journal Article; Review
MeSH Terms :: Aminobutyrates/*therapeutic use
Angiotensin II Type 1 Receptor Blockers/*therapeutic use
Heart Failure/*drug therapy
Protease Inhibitors/*therapeutic use
Tetrazoles/*therapeutic use
Aminobutyrates/adverse effects ; Aminobutyrates/economics ; Angiotensin II Type 1 Receptor Blockers/adverse effects ; Angiotensin II Type 1 Receptor Blockers/economics ; Cost-Benefit Analysis ; Drug Combinations ; Drug Costs ; Evidence-Based Medicine ; Heart Failure/diagnosis ; Heart Failure/economics ; Heart Failure/physiopathology ; Humans ; Neprilysin/antagonists & inhibitors ; Patient Safety ; Protease Inhibitors/adverse effects ; Protease Inhibitors/economics ; Quality of Life ; Randomized Controlled Trials as Topic ; Recovery of Function ; Risk Assessment ; Risk Factors ; Tetrazoles/adverse effects ; Tetrazoles/economics ; Treatment Outcome
: Czasopismo naukowe

Szczegóły

Skocz do pozycji: 4 4.

Tytuł :: [Risk of severe COVID-19 in hypertensive patients treated with renin-angiotensin-aldosterone system inhibitors].
Autorzy :: Golpe R; Servicio de Neumología, Hospital Universitario Lucus Augusti, Lugo, Spain. Electronic address: .
Pérez-de-Llano LA; Servicio de Neumología, Hospital Universitario Lucus Augusti, Lugo, Spain.
Dacal D; Servicio de Neumología, Hospital Universitario Lucus Augusti, Lugo, Spain.
Guerrero-Sande H; Servicio de Medicina Interna, Hospital Universitario Lucus Augusti, Lugo, Spain.
Pombo-Vide B; Servicio de Medicina Interna, Hospital Universitario Lucus Augusti, Lugo, Spain.
Ventura-Valcárcel P; Servicio de Medicina Interna, Hospital Universitario Lucus Augusti, Lugo, Spain.; Pokaż więcej
Transliterated Title :: Riesgo de COVID-19 grave en pacientes hipertensos tratados con inhibidores del sistema renina-angiotensina-aldosterona.
Corporate Authors :: Lugo Covid-19 team
Źródło :: Medicina clinica [Med Clin (Barc)] 2020 Dec 11; Vol. 155 (11), pp. 488-490. Date of Electronic Publication: 2020 Jun 25.
Typ publikacji :: Journal Article
MeSH Terms :: SARS-CoV-2*
Angiotensin II Type 1 Receptor Blockers/*adverse effects
COVID-19/*epidemiology
Hypertension/*drug therapy
Age Factors ; Aged ; Angiotensin II Type 1 Receptor Blockers/therapeutic use ; Cardiomyopathies/complications ; Diabetes Complications ; Female ; Hospitalization ; Humans ; Male ; Multivariate Analysis ; Prognosis ; Retrospective Studies
: Czasopismo naukowe

Szczegóły

Skocz do pozycji: 5 5.

Tytuł :: Study protocol for a multicentre, prospective cohort study of the association of angiotensin II type 1 receptor blockers on outcomes of coronavirus infection.
Autorzy :: Russell JA; Medicine, The University of British Columbia Faculty of Medicine, Vancouver, British Columbia, Canada .
Marshall JC; Surgery, University of Toronto, Toronto, Ontario, Canada.
Slutsky A; Medicine, University of Toronto Faculty of Medicine, Toronto, Ontario, Canada.
Murthy S; Paediatrics, University of British Columbia, Vancouver, British Columbia, Canada.
Sweet D; Emergency Medicine, The University of British Columbia Faculty of Medicine, Vancouver, British Columbia, Canada.
Lee T; Population and Public Health, University of British Columbia, Vancouver, British Columbia, Canada.
Singer J; Population and Public Health, University of British Columbia, Vancouver, British Columbia, Canada.
Patrick DM; Population and Public Health, University of British Columbia, Vancouver, British Columbia, Canada.
Du B; Medical ICU, Peking University, Beijing, China.
Peng Z; Medicine, Wuhan University Zhongnan Hospital, Wuhan, China.
Cheng M; Department of Medicine, McGill University, Montreal, Quebec, Canada.
Burns KD; Medicine, Ottawa Hospital Research Institute, Ottawa, Ontario, Canada.
Harhay MO; Biostatistics, Epidemiology, and Informatics, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania, USA.; Pokaż więcej
Źródło :: BMJ open [BMJ Open] 2020 Dec 07; Vol. 10 (12), pp. e040768. Date of Electronic Publication: 2020 Dec 07.
Typ publikacji :: Clinical Trial Protocol; Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :: Angiotensin II Type 1 Receptor Blockers/*therapeutic use
COVID-19/*drug therapy
Angiotensin II Type 1 Receptor Blockers/pharmacokinetics ; Humans ; Logistic Models ; Multicenter Studies as Topic ; Pandemics ; Pragmatic Clinical Trials as Topic ; Prospective Studies ; SARS-CoV-2 ; Treatment Outcome
: Czasopismo naukowe

Szczegóły

Skocz do pozycji: 6 6.

Tytuł :: In silico prediction of ARB resistance: A first step in creating personalized ARB therapy.
Autorzy :: Anderson SD; Department of Pharmaceutical Sciences, College of Pharmacy, Western University of Health Sciences, Pomona, California, United States of America.
Tabassum A; Department of Pharmaceutical Sciences, College of Pharmacy, Western University of Health Sciences, Pomona, California, United States of America.
Yeon JK; Department of Pharmaceutical Sciences, College of Pharmacy, Western University of Health Sciences, Pomona, California, United States of America.
Sharma G; Department of Pharmaceutical Sciences, College of Pharmacy, Western University of Health Sciences, Pomona, California, United States of America.
Santos P; Department of Pharmaceutical Sciences, College of Pharmacy, Western University of Health Sciences, Pomona, California, United States of America.
Soong TH; Department of Pharmaceutical Sciences, College of Pharmacy, Western University of Health Sciences, Pomona, California, United States of America.
Thu YW; Department of Pharmaceutical Sciences, College of Pharmacy, Western University of Health Sciences, Pomona, California, United States of America.
Nies I; Department of Pharmaceutical Sciences, College of Pharmacy, Western University of Health Sciences, Pomona, California, United States of America.
Kurita T; Department of Pharmaceutical Sciences, College of Pharmacy, Western University of Health Sciences, Pomona, California, United States of America.
Chandler A; Department of Pharmaceutical Sciences, College of Pharmacy, Western University of Health Sciences, Pomona, California, United States of America.
Alsamarah A; Department of Pharmaceutical Sciences, College of Pharmacy, Western University of Health Sciences, Pomona, California, United States of America.
Kanassatega RS; Department of Pharmaceutical Sciences, College of Pharmacy, Western University of Health Sciences, Pomona, California, United States of America.
Luo YL; Department of Pharmaceutical Sciences, College of Pharmacy, Western University of Health Sciences, Pomona, California, United States of America.
Botello-Smith WM; Department of Pharmaceutical Sciences, College of Pharmacy, Western University of Health Sciences, Pomona, California, United States of America.
Andresen BT; Department of Pharmaceutical Sciences, College of Pharmacy, Western University of Health Sciences, Pomona, California, United States of America.; Pokaż więcej
Źródło :: PLoS computational biology [PLoS Comput Biol] 2020 Nov 25; Vol. 16 (11), pp. e1007719. Date of Electronic Publication: 2020 Nov 25 (Print Publication: 2020).
Typ publikacji :: Journal Article
MeSH Terms :: Precision Medicine*
Angiotensin II Type 1 Receptor Blockers/*therapeutic use
Imidazoles/*therapeutic use
Tetrazoles/*therapeutic use
Angiotensin II Type 1 Receptor Blockers/chemistry ; Humans ; Imidazoles/chemistry ; Molecular Docking Simulation ; Molecular Dynamics Simulation ; Polymorphism, Single Nucleotide ; Receptor, Angiotensin, Type 1/genetics ; Reproducibility of Results ; Tetrazoles/chemistry
: Czasopismo naukowe

Szczegóły Pełny tekst Pełny tekst

Skocz do pozycji: 7 7.

Tytuł :: Telmisartan as tentative angiotensin receptor blocker therapeutic for COVID-19.
Autorzy :: Rothlin RP; Sociedad Argentina de Farmacología Clínica, Asociación Médica Argentina, Buenos Aires, Argentina.
Vetulli HM; Servicio de Electrofisiología Cardíaca, Arritmias y Marcapasos, Sanatorio Otamendi y Miroli, Buenos Aires, Argentina.
Duarte M; Hospital de Clínicas 'José de San Martín', Facultad de Medicina, Universidad de Buenos Aires, Buenos Aires, Argentina.; Segunda Cátedra de Fisiología, Facultad de Medicina, Universidad de Buenos Aires, Buenos Aires, Argentina.
Pelorosso FG; Department of Pathology, Hospital de Alta Complejidad El Calafate SAMIC, Santa Cruz, Argentina.; Pokaż więcej
Źródło :: Drug development research [Drug Dev Res] 2020 Nov; Vol. 81 (7), pp. 768-770. Date of Electronic Publication: 2020 May 01.
Typ publikacji :: Journal Article
MeSH Terms :: Angiotensin II Type 1 Receptor Blockers/*therapeutic use
COVID-19/*drug therapy
SARS-CoV-2/*physiology
Telmisartan/*therapeutic use
Angiotensin II Type 1 Receptor Blockers/pharmacology ; Angiotensin-Converting Enzyme 2/metabolism ; COVID-19/metabolism ; Clinical Trials, Phase II as Topic ; Humans ; Lung/metabolism ; Lung/virology ; Pandemics ; Protein Binding/drug effects ; SARS-CoV-2/drug effects ; SARS-CoV-2/metabolism ; Spike Glycoprotein, Coronavirus/metabolism ; Telmisartan/pharmacology ; Virus Internalization/drug effects
: Czasopismo naukowe

Szczegóły

Skocz do pozycji: 8 8.

Tytuł :: The Potential Benefit of Telmisartan to Protect Overweight Patients with COPD from the Acquisition of COVID-19.
Autorzy :: Kow CS; School of Postgraduate Studies, International Medical University, Kuala Lumpur, Malaysia.
Hasan SS; Department of Pharmacy, University of Huddersfield, Huddersfield, UK.; Pokaż więcej
Źródło :: Obesity (Silver Spring, Md.) [Obesity (Silver Spring)] 2020 Nov; Vol. 28 (11), pp. 2035. Date of Electronic Publication: 2020 Sep 23.
Typ publikacji :: Letter
MeSH Terms :: Angiotensin II Type 1 Receptor Blockers/*therapeutic use
Betacoronavirus/*pathogenicity
Coronavirus Infections/*drug therapy
Overweight/*drug therapy
Pneumonia, Viral/*drug therapy
Pulmonary Disease, Chronic Obstructive/*complications
Telmisartan/*therapeutic use
Angiotensin II Type 1 Receptor Blockers/pharmacology ; Animals ; COVID-19 ; Female ; Humans ; Male ; Mice ; Overweight/complications ; Pandemics ; Rats ; SARS-CoV-2 ; Telmisartan/pharmacology
: Opinia redakcyjna

Szczegóły

Skocz do pozycji: 9 9.

Tytuł :: Can a Combination of AT1R Antagonist and Vitamin D Treat the Lung Complication of COVID-19?
Autorzy :: Rafiullah M; Strategic Center for Diabetes Research, College of Medicine, King Saud University, Riyadh, Saudi Arabia. Electronic address: .; Pokaż więcej
Źródło :: The American journal of the medical sciences [Am J Med Sci] 2020 Oct; Vol. 360 (4), pp. 338-341. Date of Electronic Publication: 2020 Jul 15.
Typ publikacji :: Journal Article; Review
MeSH Terms :: Angiotensin II Type 1 Receptor Blockers/*therapeutic use
Coronavirus Infections/*drug therapy
Pneumonia, Viral/*drug therapy
Severe Acute Respiratory Syndrome/*drug therapy
Vitamin D/*therapeutic use
Vitamins/*therapeutic use
Angiotensin II Type 1 Receptor Blockers/pharmacology ; Angiotensin-Converting Enzyme 2 ; Animals ; Betacoronavirus ; COVID-19 ; Coronavirus Infections/blood ; Coronavirus Infections/complications ; Host-Pathogen Interactions ; Humans ; Pandemics ; Peptidyl-Dipeptidase A/blood ; Pneumonia, Viral/blood ; Pneumonia, Viral/complications ; Renin-Angiotensin System/drug effects ; SARS-CoV-2 ; Severe Acute Respiratory Syndrome/virology ; Virus Internalization ; Vitamin D/pharmacology ; Vitamins/pharmacology
SCR Protocol :: COVID-19 drug treatment
: Czasopismo naukowe

Szczegóły

Skocz do pozycji: 10 10.

Tytuł :: Real-world treatment switching to sacubitril/valsartan in patients with heart failure with reduced ejection fraction: A cohort study.
Autorzy :: Ganesananthan S; School of Medicine, Cardiff University, Cardiff, UK .; Department of Cardiology, University Hospital of Wales, Cardiff, UK.
Shah N; Department of Cardiology, University Hospital of Wales, Cardiff, UK.
Shah P; Department of Cardiology, University Hospital of Wales, Cardiff, UK.
Elsayed H; Department of Cardiology, University Hospital of Wales, Cardiff, UK.
Phillips J; Department of Cardiology, University Hospital of Wales, Cardiff, UK.
Parkes A; Department of Cardiology, University Hospital of Wales, Cardiff, UK.
Morgan A; Health Economics and Outcomes Research Ltd, Cardiff University, Cardiff, South Glamorgan, UK.
Yousef Z; Department of Cardiology, University Hospital of Wales, Cardiff, UK.; Pokaż więcej
Źródło :: Open heart [Open Heart] 2020 Oct; Vol. 7 (2).
Typ publikacji :: Journal Article
MeSH Terms :: Drug Substitution*
Aminobutyrates/*therapeutic use
Angiotensin II Type 1 Receptor Blockers/*therapeutic use
Heart Failure/*drug therapy
Protease Inhibitors/*therapeutic use
Stroke Volume/*drug effects
Tetrazoles/*therapeutic use
Ventricular Function, Left/*drug effects
Aged ; Aminobutyrates/adverse effects ; Angiotensin II Type 1 Receptor Blockers/adverse effects ; Drug Combinations ; Echocardiography ; Female ; Heart Failure/diagnostic imaging ; Heart Failure/physiopathology ; Humans ; Male ; Middle Aged ; Neprilysin/antagonists & inhibitors ; Protease Inhibitors/adverse effects ; Quality of Life ; Recovery of Function ; Retrospective Studies ; Tetrazoles/adverse effects ; Time Factors ; Treatment Outcome
: Czasopismo naukowe

Szczegóły

Skocz do pozycji: 11 11.

Tytuł :: Valsartan Versus Amlodipine Effect on Left Ventricular Multidirectional Deformation and Adipocytokines Levels in Hypertensive Patients: Speckle Tracking Echocardiography.
Autorzy :: Khairat I; Department of Cardiology, Faculty of Medicine, Tanta University, El-Gharbia, Egypt.
Khedr L; Department of Cardiology, Faculty of Medicine, Tanta University, El-Gharbia, Egypt.
Werida R; Department of Clinical Pharmacy, Faculty of Pharmacy, Damanhour University, El-Behaira, 22511, Egypt. .; Pokaż więcej
Źródło :: High blood pressure & cardiovascular prevention : the official journal of the Italian Society of Hypertension [High Blood Press Cardiovasc Prev] 2020 Oct; Vol. 27 (5), pp. 379-388. Date of Electronic Publication: 2020 Jul 23.
Typ publikacji :: Comparative Study; Journal Article; Randomized Controlled Trial
MeSH Terms :: Echocardiography*
Adipokines/*blood
Amlodipine/*therapeutic use
Angiotensin II Type 1 Receptor Blockers/*therapeutic use
Antihypertensive Agents/*therapeutic use
Calcium Channel Blockers/*therapeutic use
Hypertension/*therapy
Valsartan/*therapeutic use
Ventricular Function, Left/*drug effects
Ventricular Remodeling/*drug effects
Adiponectin/blood ; Adult ; Amlodipine/adverse effects ; Angiotensin II Type 1 Receptor Blockers/adverse effects ; Antihypertensive Agents/adverse effects ; Biomarkers/blood ; C-Reactive Protein/metabolism ; Calcium Channel Blockers/adverse effects ; Egypt ; Female ; Humans ; Hypertension/blood ; Hypertension/diagnostic imaging ; Hypertension/physiopathology ; Leptin/blood ; Male ; Middle Aged ; Predictive Value of Tests ; Time Factors ; Treatment Outcome ; Tumor Necrosis Factor-alpha/blood ; Valsartan/adverse effects
: Czasopismo naukowe

Szczegóły

Skocz do pozycji: 12 12.

Tytuł :: [Renin-angiotensin system blockers and COVID-19 infection].
Autorzy :: Ruilope LM; Cardiorenal Translational Laboratory, Institute of Research i+12, Hospital Universitario 12 de Octubre, Madrid, España; Unidad de Hipertensión, Hospital Universitario 12 de Octubre, Madrid, España; Universidad Europea Madrid, Madrid, España; CIBER-CV, Hospital Universitario 12 de Octubre, Madrid, España. Electronic address: .
Garcia Donaire JA; Unidad de Hipertensión Arterial, Hospital Clínico San Carlos, Madrid, España; Unidad de Hipertensión. Servicio de Medicina Interna, Hospital Mutua Terrassa, Terrassa, Barcelona, España.
de la Sierra A; Departament de Medicina, Universitat de Barcelona, Barcelona, España; Unidad de Hipertensión, Servicio de Medicina Interna, Hospital Mutua Terrassa, Terrassa, España.; Pokaż więcej
Transliterated Title :: Bloqueantes del sistema renina-angiotensina e infección por COVID-19.
Źródło :: Hipertension y riesgo vascular [Hipertens Riesgo Vasc] 2020 Jul - Sep; Vol. 37 (3), pp. 99-100. Date of Electronic Publication: 2020 Apr 16.
Typ publikacji :: Editorial
MeSH Terms :: Angiotensin II Type 1 Receptor Blockers/*administration & dosage
Angiotensin-Converting Enzyme Inhibitors/*administration & dosage
Coronavirus Infections/*complications
Pneumonia, Viral/*complications
Renin-Angiotensin System/*drug effects
Angiotensin II Type 1 Receptor Blockers/adverse effects ; Angiotensin II Type 1 Receptor Blockers/pharmacology ; Angiotensin-Converting Enzyme Inhibitors/adverse effects ; Angiotensin-Converting Enzyme Inhibitors/pharmacology ; Betacoronavirus/isolation & purification ; COVID-19 ; Coronavirus Infections/virology ; Humans ; Hypertension/drug therapy ; Hypertension/epidemiology ; Pandemics ; Pneumonia, Viral/virology ; SARS-CoV-2
: Opinia redakcyjna

Szczegóły

Skocz do pozycji: 13 13.

Tytuł :: Pharmacodynamic and pharmacokinetic effects of S086, a novel angiotensin receptor neprilysin inhibitor.
Autorzy :: Sun J; Shenzhen Salubris Pharmaceutical Co., Ltd., Shenzhen, Guangdong, China. Electronic address: .
Xu W; Shenzhen Salubris Pharmaceutical Co., Ltd., Shenzhen, Guangdong, China.
Hua H; Shenzhen Salubris Pharmaceutical Co., Ltd., Shenzhen, Guangdong, China.
Xiao Y; Shenzhen Salubris Pharmaceutical Co., Ltd., Shenzhen, Guangdong, China.
Chen X; Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China.
Gao Z; Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China.
Li S; Shenzhen Salubris Pharmaceutical Co., Ltd., Shenzhen, Guangdong, China.
Jing X; Shenzhen Salubris Pharmaceutical Co., Ltd., Shenzhen, Guangdong, China.
Du F; WuXi AppTec (Shanghai) Co., Ltd., Shanghai, China.
Sun G; WuXi AppTec (Shanghai) Co., Ltd., Shanghai, China.; Pokaż więcej
Źródło :: Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie [Biomed Pharmacother] 2020 Sep; Vol. 129, pp. 110410. Date of Electronic Publication: 2020 Jun 20.
Typ publikacji :: Comparative Study; Journal Article
MeSH Terms :: Angiotensin II Type 1 Receptor Blockers/*pharmacology
Heart Failure/*drug therapy
Neprilysin/*antagonists & inhibitors
Protease Inhibitors/*pharmacology
Administration, Oral ; Aminobutyrates/pharmacology ; Angiotensin II Type 1 Receptor Blockers/administration & dosage ; Animals ; Cardiomegaly/etiology ; Cardiomegaly/physiopathology ; Cardiomegaly/prevention & control ; Chronic Disease ; Disease Models, Animal ; Dogs ; Drug Combinations ; Heart Failure/etiology ; Heart Failure/physiopathology ; Myocardial Ischemia/complications ; Myocardial Ischemia/physiopathology ; Protease Inhibitors/administration & dosage ; Rats, Sprague-Dawley ; Recovery of Function ; Stroke Volume/drug effects ; Tetrazoles/pharmacology ; Ventricular Function, Left/drug effects
: Czasopismo naukowe

Szczegóły

Skocz do pozycji: 14 14.

Tytuł :: Risk and prognosis of COVID-19 in patients treated with renin-angiotensin-aldosterone inhibitors.
Autorzy :: Vistisen ST; From the Department of Clinical Medicine, Aarhus University, Aarhus (STV), Department of Infectious Diseases, Aalborg University Hospital, Aalborg, Denmark (JB), Department of Anaesthesiology, University Medical Centre Groningen, University of Groningen, Groningen, The Netherlands (TWLS) and Department of Biomedicine, Aarhus University, Aarhus, Denmark (US).
Bodilsen J
Scheeren TWL
Simonsen U; Pokaż więcej
Źródło :: European journal of anaesthesiology [Eur J Anaesthesiol] 2020 Sep; Vol. 37 (9), pp. 739-742.
Typ publikacji :: Editorial
MeSH Terms :: Angiotensin II Type 1 Receptor Blockers/*therapeutic use
Angiotensin-Converting Enzyme Inhibitors/*therapeutic use
Coronavirus Infections/*drug therapy
Pneumonia, Viral/*drug therapy
Renin-Angiotensin System/*drug effects
Angiotensin II Type 1 Receptor Blockers/adverse effects ; Angiotensin-Converting Enzyme Inhibitors/adverse effects ; Antihypertensive Agents/therapeutic use ; COVID-19 ; Coronavirus Infections/complications ; Humans ; Observational Studies as Topic ; Pandemics ; Pneumonia, Viral/complications ; Prognosis ; Risk Assessment
: Opinia redakcyjna

Szczegóły

Skocz do pozycji: 15 15.

Tytuł :: Rationale and design of the PRAETORIAN-COVID trial: A double-blind, placebo-controlled randomized clinical trial with valsartan for PRevention of Acute rEspiraTORy dIstress syndrome in hospitAlized patieNts with SARS-COV-2 Infection Disease.
Autorzy :: Gommans DHF; Department of Cardiology, Radboudumc, Nijmegen, the Netherlands. Electronic address: .
Nas J; Department of Cardiology, Radboudumc, Nijmegen, the Netherlands.
Pinto-Sietsma SJ; Department of Vascular Medicine, Amsterdam UMC, Amsterdam, the Netherlands.
Koop Y; Department of Cardiology, Radboudumc, Nijmegen, the Netherlands.
Konst RE; Department of Cardiology, Radboudumc, Nijmegen, the Netherlands.
Mensink F; Department of Cardiology, Radboudumc, Nijmegen, the Netherlands.
Aarts GWA; Department of Cardiology, Radboudumc, Nijmegen, the Netherlands.
Konijnenberg LSF; Department of Cardiology, Radboudumc, Nijmegen, the Netherlands.
Cortenbach K; Department of Cardiology, Radboudumc, Nijmegen, the Netherlands.
Verhaert DVM; Department of Cardiology, Radboudumc, Nijmegen, the Netherlands; Department of Cardiology, Cardiovascular Research Institute Maastricht (CARIM), Maastricht University Medical Center (MUMC+), Maastricht, the Netherlands.
Thannhauser J; Department of Cardiology, Radboudumc, Nijmegen, the Netherlands.
Mol JQ; Department of Cardiology, Radboudumc, Nijmegen, the Netherlands.
Rooijakkers MJP; Department of Cardiology, Radboudumc, Nijmegen, the Netherlands.
Vos JL; Department of Cardiology, Radboudumc, Nijmegen, the Netherlands.
van Rumund A; Department of Neurology, Radboudumc, Nijmegen, the Netherlands.
Vart P; Department of Biostatistics, Radboudumc, Nijmegen, the Netherlands.
Hassing RJ; Department of Internal Medicine, Rijnstate Hospital, Arnhem, the Netherlands.
Cornel JH; Department of Cardiology, Radboudumc, Nijmegen, the Netherlands; Department of Cardiology, Noordwest Ziekenhuisgroep, Alkmaar, the Netherlands.
de Jager CPC; Department of Intensive Care, Jeroen Bosch Hospital, 's-Hertogenbosch, the Netherlands.
van den Heuvel MM; Department of Pulmonary diseases, Radboudumc, Nijmegen, the Netherlands.
van der Hoeven HG; Department of Intensive Care, Radboudumc, Nijmegen, the Netherlands.
Verbon A; Department of Medical Microbiology and Infectious Diseases, ErasmusMC, Rotterdam, the Netherlands.
Pinto YM; Department of Cardiology, Amsterdam UMC, Amsterdam, the Netherlands.
van Royen N; Department of Cardiology, Radboudumc, Nijmegen, the Netherlands.
van Kimmenade RRJ; Department of Cardiology, Radboudumc, Nijmegen, the Netherlands.
de Leeuw PW; Department of Internal Medicine, Maastricht UMC, Maastricht, the Netherlands.
van Agtmael MA; Department of Internal Medicine, Amsterdam UMC, Amsterdam, the Netherlands.
Bresser P; Department of Pulmonary Diseases, Onze Lieve Vrouwe Gasthuis, Amsterdam, the Netherlands.
van Gilst WH; Department of Experimental Cardiology, UMCG, Groningen, the Netherlands.
Vonk-Noordergraaf A; Department of Pulmonary Diseases, Amsterdam UMC, Amsterdam, the Netherlands.
Tijssen JGP; Department of Cardiology, Amsterdam UMC, Amsterdam, the Netherlands.
van Royen N; Department of Cardiology, Radboudumc, Nijmegen, the Netherlands.
de Jager CPC; Department of Intensive Care, Jeroen Bosch Hospital, 's-Hertogenbosch, the Netherlands.
van den Heuvel MM; Department of Pulmonary diseases, Radboudumc, Nijmegen, the Netherlands.
van der Hoeven HG; Department of Intensive Care, Radboudumc, Nijmegen, the Netherlands.
Verbon A; Department of Medical Microbiology and Infectious Diseases, ErasmusMC, Rotterdam, the Netherlands.
Pinto YM; Department of Cardiology, Amsterdam UMC, Amsterdam, the Netherlands.
van Kimmenade RRJ; Department of Cardiology, Radboudumc, Nijmegen, the Netherlands.; Pokaż więcej
Corporate Authors :: Event committee
Data Safety Monitoring Board
Steering committee
Źródło :: American heart journal [Am Heart J] 2020 Aug; Vol. 226, pp. 60-68. Date of Electronic Publication: 2020 May 21.
Typ publikacji :: Clinical Trial Protocol; Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :: Betacoronavirus*
Coronary Care Units*
Randomized Controlled Trials as Topic*
Angiotensin II Type 1 Receptor Blockers/*therapeutic use
Coronavirus Infections/*complications
Pneumonia, Viral/*complications
Respiratory Distress Syndrome/*prevention & control
Valsartan/*therapeutic use
Adult ; Angiotensin II Type 1 Receptor Blockers/administration & dosage ; COVID-19 ; Coronavirus Infections/mortality ; Double-Blind Method ; Drug Administration Schedule ; Humans ; Inpatients ; Multicenter Studies as Topic ; Netherlands ; Pandemics ; Placebos/therapeutic use ; Pneumonia, Viral/mortality ; Respiration, Artificial ; Respiratory Distress Syndrome/mortality ; SARS-CoV-2 ; Time Factors ; Valsartan/administration & dosage
: Czasopismo naukowe

Szczegóły

Skocz do pozycji: 16 16.

Tytuł :: Reflections of the Angiotensin Receptor Blocker Recall by the FDA and Repercussions on Healthcare.
Autorzy :: Gillette M; Section of Cardiology, Baylor College of Medicine and the Michael DeBakey VA Medical Center, 2002 Holcombe Blvd (111), Houston, TX, 77030, USA.
Taylor A; Section of Cardiology, Baylor College of Medicine and the Michael DeBakey VA Medical Center, 2002 Holcombe Blvd (111), Houston, TX, 77030, USA.
Butulija D; Section of Cardiology, Baylor College of Medicine and the Michael DeBakey VA Medical Center, 2002 Holcombe Blvd (111), Houston, TX, 77030, USA.
Kadiyala H; Section of Cardiology, Baylor College of Medicine and the Michael DeBakey VA Medical Center, 2002 Holcombe Blvd (111), Houston, TX, 77030, USA.
Jneid H; Section of Cardiology, Baylor College of Medicine and the Michael DeBakey VA Medical Center, 2002 Holcombe Blvd (111), Houston, TX, 77030, USA. .; Pokaż więcej
Źródło :: Cardiovascular drugs and therapy [Cardiovasc Drugs Ther] 2020 Aug; Vol. 34 (4), pp. 579-584.
Typ publikacji :: Editorial; Review
MeSH Terms :: Drug Approval*
Drug Contamination*
Drug Recalls*
Quality Control*
Angiotensin II Type 1 Receptor Blockers/*analysis
Carcinogens/*analysis
Drug Industry/*standards
United States Food and Drug Administration/*standards
Angiotensin II Type 1 Receptor Blockers/adverse effects ; Humans ; Patient Safety ; Risk Assessment ; Risk Factors ; United States
: Recenzja

Szczegóły

Skocz do pozycji: 17 17.

Tytuł :: Renin-angiotensin system inhibitors in management of hypertension during the COVID-19 pandemic.
Autorzy :: Dworakowska D; Department of Hypertension and Diabetes, Medical University of Gdansk, Gdansk, Poland. .; Guys Richard Dimbleby Department of Cancer Research, Kings College London, London, UK.; London International Clinic, London, UK.
Grossman AB; Centre for Endocrinology, Barts and the London School of Medicine, Queen Mary University of London, London, UK.; Oxford Centre for Diabetes, Endocrinology and Metabolism, University of Oxford, Oxford, UK.; Pokaż więcej
Źródło :: Journal of physiology and pharmacology : an official journal of the Polish Physiological Society [J Physiol Pharmacol] 2020 Apr; Vol. 71 (2). Date of Electronic Publication: 2020 Jul 02.
Typ publikacji :: Journal Article; Review
MeSH Terms :: Angiotensin II Type 1 Receptor Blockers/*administration & dosage
Angiotensin-Converting Enzyme Inhibitors/*administration & dosage
Coronavirus Infections/*physiopathology
Pneumonia, Viral/*physiopathology
Angiotensin II Type 1 Receptor Blockers/adverse effects ; Angiotensin II Type 1 Receptor Blockers/pharmacology ; Angiotensin-Converting Enzyme Inhibitors/adverse effects ; Angiotensin-Converting Enzyme Inhibitors/pharmacology ; Animals ; Betacoronavirus/isolation & purification ; COVID-19 ; Coronavirus Infections/virology ; Humans ; Hypertension/drug therapy ; Pandemics ; Pneumonia, Viral/virology ; Renin-Angiotensin System/drug effects ; SARS-CoV-2
: Czasopismo naukowe

Szczegóły

Skocz do pozycji: 18 18.

Tytuł :: Renin-Angiotensin System Blockers and the COVID-19 Pandemic: At Present There Is No Evidence to Abandon Renin-Angiotensin System Blockers.
Autorzy :: Danser AHJ; From the Division of Pharmacology and Vascular Medicine, Department of Internal Medicine, Erasmus MC, Rotterdam, The Netherlands (A.H.J.D.).
Epstein M; Division of Nephrology and Hypertension, University of Miami Miller School of Medicine, FL (M.E.).
Batlle D; Division of Nephrology/Hypertension, Department of Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL (D.B.).; Pokaż więcej
Źródło :: Hypertension (Dallas, Tex. : 1979) [Hypertension] 2020 Jun; Vol. 75 (6), pp. 1382-1385. Date of Electronic Publication: 2020 Mar 25.
Typ publikacji :: Journal Article; Research Support, N.I.H., Extramural
MeSH Terms :: Betacoronavirus*
Angiotensin II Type 1 Receptor Blockers/*pharmacology
Angiotensin-Converting Enzyme Inhibitors/*pharmacology
Coronavirus Infections/*drug therapy
Peptidyl-Dipeptidase A/*physiology
Pneumonia, Viral/*drug therapy
Receptors, Virus/*physiology
Renin-Angiotensin System/*drug effects
Renin-Angiotensin System/*physiology
Angiotensin II Type 1 Receptor Blockers/therapeutic use ; Angiotensin-Converting Enzyme 2 ; Angiotensin-Converting Enzyme Inhibitors/therapeutic use ; Animals ; COVID-19 ; Coronavirus Infections/metabolism ; Coronavirus Infections/physiopathology ; Humans ; Pandemics ; Pneumonia, Viral/metabolism ; Pneumonia, Viral/physiopathology ; Receptors, Virus/antagonists & inhibitors ; SARS-CoV-2
SCR Protocol :: COVID-19 drug treatment
: Czasopismo naukowe

Szczegóły

Skocz do pozycji: 19 19.

Tytuł :: A potential protective role of losartan against coronavirus-induced lung damage.
Autorzy :: Zeinalian M; Department of Genetics and Molecular Biology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran.
Salari-Jazi A; Department of Microbiology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran.
Jannesari A; School of Pharmacy and Pharmaceutical Sciences, Isfahan University of Medical Sciences, Isfahan, Iran.
Khanahmad H; Department of Genetics and Molecular Biology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran.; Pokaż więcej
Źródło :: Infection control and hospital epidemiology [Infect Control Hosp Epidemiol] 2020 Jun; Vol. 41 (6), pp. 752-753.
Typ publikacji :: Letter
MeSH Terms :: Betacoronavirus*
Angiotensin II Type 1 Receptor Blockers/*therapeutic use
Coronavirus Infections/*drug therapy
Losartan/*therapeutic use
Lung/*drug effects
Pneumonia, Viral/*drug therapy
Angiotensin II Type 1 Receptor Blockers/pharmacology ; COVID-19 ; Coronavirus Infections/pathology ; Humans ; Losartan/pharmacology ; Lung/pathology ; Pandemics ; Pneumonia, Viral/pathology ; SARS-CoV-2
: Opinia redakcyjna

Szczegóły

Skocz do pozycji: 20 20.

Tytuł :: Reverse Cardiac Remodeling and Outcome After Initiation of Sacubitril/Valsartan.
Autorzy :: Januzzi JL Jr; Massachusetts General Hospital, Boston, MA (J.L.J., A.C.).; Detroit Medical Center, MI (I.L.P.).
Camacho A; Massachusetts General Hospital, Boston, MA (J.L.J., A.C.).
Piña IL; Detroit Medical Center, MI (I.L.P.).
Rocha R; Novartis Pharmaceuticals, East Hanover, NJ (R.R., K.M.W., M.F.P.).
Williamson KM; Novartis Pharmaceuticals, East Hanover, NJ (R.R., K.M.W., M.F.P.).
Maisel AS; University of California, San Diego School of Medicine (A.S.M.).
Felker GM; Duke University Medical Center and Duke Clinical Research Institute, Durham, NC (G.M.F.).
Prescott MF; Novartis Pharmaceuticals, East Hanover, NJ (R.R., K.M.W., M.F.P.).
Butler J; University of Mississippi Medical Center, Jackson, MS (J.B.).
Solomon SD; Brigham and Women's Hospital, Boston, MA (S.D.S.).; Pokaż więcej
Corporate Authors :: PROVE-HF Investigators
Źródło :: Circulation. Heart failure [Circ Heart Fail] 2020 Jun; Vol. 13 (6), pp. e006946. Date of Electronic Publication: 2020 Jun 02.
Typ publikacji :: Letter; Research Support, Non-U.S. Gov't
MeSH Terms :: Aminobutyrates/*therapeutic use
Angiotensin II Type 1 Receptor Blockers/*therapeutic use
Heart Failure/*drug therapy
Protease Inhibitors/*therapeutic use
Tetrazoles/*therapeutic use
Ventricular Function, Left/*drug effects
Ventricular Remodeling/*drug effects
Aminobutyrates/adverse effects ; Angiotensin II Type 1 Receptor Blockers/adverse effects ; Disease Progression ; Drug Combinations ; Heart Failure/diagnostic imaging ; Heart Failure/mortality ; Heart Failure/physiopathology ; Hospitalization ; Humans ; Neprilysin/antagonists & inhibitors ; Protease Inhibitors/adverse effects ; Recovery of Function ; Tetrazoles/adverse effects ; Time Factors ; Treatment Outcome
: Raport

Szczegóły

Informacja

Prolib Integro - strona głównaUniwersytet Ekonomiczny we Wrocławiu

Wyszukujesz frazę ""Angiotensin II Type 1 Receptor Blockers"" wg kryterium: Temat

Źródło danych

Ogranicz do:

Ogranicz do bazy

Typ dokumentu

Temat

Wydawca

Publikacja

Język